| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH) |
Ongoing |
Seralutinib |
3 |
GB002-3101 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials |
Ongoing |
OAV101 (formerly AVXS-101) |
3 |
COAV101A12308 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure |
Ongoing |
Baxdrostat |
3 |
D6972C00003 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam),King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh) |
| Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours |
Ongoing |
BI 907828/ brigimadlin |
2 |
1403-0011 |
King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease |
Ongoing |
roxadustat |
3 |
1517-CL-1003 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study |
Rejected |
BRENTUXIMAB VEDOTIN |
3 |
RJ19/119/J |
King Abdulaziz Medical City NG (Riyadh) |
| The effect of (Oligonol) and (Oligonol + metformin) on the components of Metabolic Syndrome in obese individuals- A randomized, double-blind, factorial clinical trial. |
Terminated |
Oligonol |
3 |
SDRG- Amino Up 1 |
KFMRC-J |
| "An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure " |
Completed |
Dapagliflozin |
3 |
D169CC00001 |
KKUH |
| Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide |
Ongoing |
Talquetamab |
3 |
80202135EBF3001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| A Prospective, Multicenter, Single-Arm, Open-Label, Phase 3 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging. (RESTORE) |
Completed |
Selexipag |
3 |
67896049PAH4005 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
